N-{[4'-(2-benzyl-1-benzofuran-3-yl)biphenyl-4-yl]sulfonyl}-N-[3-(trifluoromethoxy)benzyl]glycine | 796739-51-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: N-{[4'-(2-benzyl-1-benzofuran-3-yl)biphenyl-4-yl]sulfonyl}-N-[3-(trifluoromethoxy)benzyl]glycine
• 英文别名: 2-[[4-[4-(2-Benzyl-1-benzofuran-3-yl)phenyl]phenyl]sulfonyl-[[3-(trifluoromethoxy)phenyl]methyl]amino]acetic acid
• CAS: 796739-51-0
• 化学式: C₃₇H₂₈F₃NO₆S
• 分子量: 671.694
• InChiKey: ULESQHITDRAUPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  48
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• Phenyl substituted carboxylic acids
  申请人：Whitehouse Darren

  公开号：US20050004369A1

  公开（公告）日：2005-01-06

  Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明涉及公式（A）的化合物和药学上可接受的盐，其用于治疗与胰岛素抵抗、瘦素抵抗或高血糖相关的代谢紊乱。本发明的化合物包括蛋白酪氨酸磷酸酶（尤其是蛋白酪氨酸磷酸酶-1B（PTP-1B））的抑制剂，其对于治疗糖尿病和其他PTP介导的疾病（如癌症、神经退行性疾病等）有用。本发明还涉及包括本发明化合物的制药组合物以及使用这些化合物治疗上述疾病的方法。
• PHENYL SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B
  申请人：The Institutes for Pharmaceutical Discovery, LLC

  公开号：EP1620422A2

  公开（公告）日：2006-02-01
• JP2006525365A
  申请人：——

  公开号：JP2006525365A

  公开（公告）日：2006-11-09
• US7524878B2
  申请人：——

  公开号：US7524878B2

  公开（公告）日：2009-04-28
• [EN] PHENYL SUBSTITUTED CARBOXYLIC ACIDS<br/>[FR] ACIDES CARBOXYLIQUES SUBSTITUES PAR PHENYLE
  申请人：INST OF PHARMACEUTICAL DISCOVE

  公开号：WO2004099170A2

  公开（公告）日：2004-11-18

  Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.